Structure base drug discovery company
Amura Holdings Ltd., Minerva Building, Babraham Research Campus, Babraham, CB22 3AT, U.K.
Home
Company
Technologies
AMcore™
Programmes
News
Contact
Sitemap
Search
 
 
     
 

Technologies

Amura have two main platforms;

(1) AMcore which provides a powerful platform for the discovery of drugs with potential utility against a range of commercially attractive therapeutics targets.

Download the AMcore™ factsheet here      
 

(2) ß-lactamase inhibitors AM-112 is a lead candidate oxapenem  ß-lactamase inhibitor (BLI) that exhibits substantially improved chemical stability within this otherwise labile class of compounds. AM-112 is an ideal combination partner for resistance susceptible ß-lactam antibiotics including: penicillins, cephalosporins and carbapenems to be used in first-line i.v. treatments for broad-spectrum hospital-acquired bacterial infections.  Amura is seeking partners with a common vision towards progression and commercialisation of these combination therapeutics.

Download the ß-lactamase inhibitor (BLI) here  


 

 
     
Email: amura@amura.co.uk
Phone: +44(0)1223 839797 Fax: +44(0)1223 839898 Copyright © 2009 Amura Holdings Ltd.